Insomnia is an extremely frustrating problem for many older patients and their clinicians. In this randomized double-blind trial from Italy, researchers enrolled 43 residents (mean age ...

These results are almost too good to be true — an apparently safe and highly effective treatment for primary insomnia. Additional research to replicate these findings in other populations and to ...

Are you searching for medications to treat 'Insomnia'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Insomnia. The page includes both the ...

Repetitive transcranial magnetic stimulation (rTMS) has emerged as a new approach in this therapeutic area. The mechanisms responsible for the analgesic effect of rTMS are unknown, however ...

Specifically, I have expertise in Alpha-Stim treatment for chronic pain, and assessment of military/deployment related PTSD. I am a trauma trained psychotherapist in EMDR, CPT and Prolonged Exposure.

a device used to treat chronic insomnia. The Belfast-based company has developed a non-invasive device that delivers electrical stimulation to the vestibular nerve of the brain. This modulates the ...

Primary insomnia is a sleep disorder involving difficulty falling asleep, staying asleep, or experiencing non-restorative sleep. Lifestyle changes, medication, and therapy may be considered for ...

A brain implant can help people with Parkinson’s disease deal with movement problems during the day and insomnia at night ... is the future of deep brain stimulation for Parkinson’s disease ...

Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It is designed for easy ...

Generation Alpha includes those born in 2010 and onward. Generation Alpha, the youngest generation, born between 2010 and 2024, is quickly emerging as an influential demographic and is poised to ...

2022 also proved to be a strong year for the aristocrats, as they earned 15.15% of alpha on the S&P, making up for 3 years of underperformance. 2023 and 2024 have been more sour periods for the ...